Navigation Links
Vion Reports 2007 Fourth Quarter and Year-End Results
Date:3/17/2008

development 5,519 4,987 24,198 21,484

Marketing, general and

administrative 2,042 1,527 8,429 5,787

Total operating expenses 7,561 6,514 32,627 27,271

Loss from operations (7,511) (6,508) (32,561) (27,249)

Interest income 787 434 3,390 1,994

Interest expense (1,483) -- (5,135) --

Other expense, net (26) (19) (30) (50)

Loss before income taxes (8,233) (6,093) (34,336) (25,305)

Income tax provision (benefit) (74) 8 (343) 42

Net loss ($8,159) ($6,101) ($33,993)($25,347)

Basic and diluted loss per share(1) ($1.18) ($0.92) ($5.05) ($3.83)

Weighted-average number of shares

of common stock outstanding(1) 6,898 6,628 6,737 6,620

(1) Adjusted for all periods presented to reflect the Company's

one-for-ten reverse stock split effected February 20, 2008.

CONDENSED CONSOLIDATED BALANCE SHEET DATA

December 31,

(In thousands) 2007 2006

Cash and cash equivalents $61,067 $30,914

Total assets 63,195 31,856

Convertible senior notes 54,275 --

Total liabilities 61,988 6,402

Shareholders' equity 1,207 25,454


'/>"/>
SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. AutoImmune Inc. Reports 2007 Fourth Quarter and Year End Financial Results
2. Renovis Reports Fourth Quarter and Full Year 2007 Financial Results
3. Warner Chilcott Reports the Death of Its Director James Andress
4. Nile Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results
5. Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results
6. Unigene Restates Policy on Analyst Reports
7. NPS Pharmaceuticals Reports 2007 Financial Results
8. Trubion Pharmaceuticals Inc. Reports Fourth-Quarter and Year-Ended 2007 Financial Results and Provides 2008 Financial Outlook
9. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
10. Dendreon Reports Fourth Quarter and 2007 Year End Financial Results
11. MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... At the request of the AMA, the ... for the public comment period (Docket No. FAA-2014-0396) for ... established by Congress as part of the FAA Modernization ... the new deadline for comments as September 23, 2014. ... published in the Federal Register on July 25, 2014, ...
(Date:7/25/2014)... , July 25, 2014 Sinovac Biotech Ltd. ... products in China , today announced that ... quarter ended June 30, 2014, after market close on Thursday, ... call prior to the market opening on Friday, August 15, ... 8:00 p.m. China Standard Time) to review the Company,s financial ...
(Date:7/24/2014)... July 24, 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the ... randomized, active control Phase 3 study of Zerenex (ferric ... for the treatment of hyperphosphatemia in patients with end-stage ... binding and iRon delivery with FErric CiTrate in EsrD) ... the American Society of Nephrology ( JASN ). ...
(Date:7/24/2014)... RIDGE, Tenn., July 24, 2014 -- A novel combination ... the Department of Energy,s Oak Ridge National Laboratory an ... for its unusual physical and electrochemical properties. , ... how oxygen affects the surface of a perovskite manganite, ... behavior. The new avenue to understand surface behavior could ...
Breaking Biology Technology:FAA Grants Comment Extension at the Request of AMA 2Sinovac to Host Conference Call to Report Second Quarter 2014 Unaudited Financial Results 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4ORNL study reveals new characteristics of complex oxide surfaces 2
... - Company to Host Conference Call at 4:30 p.m. ET ... PCYC ) today reported financial results for its fourth ... for the fourth quarter of,fiscal 2008 was $4.6 million, or ... or $0.27 per share, for the fourth quarter of fiscal ...
... is accelerating improvements for converting plant biomass into biofuelas ... needs, reports Eddy Rubin, Director of the U.S. Department ... August 14 edition of the journal Nature . ... a path forward for how emerging genomic technologies will ...
... SGX Pharmaceuticals, Inc.,(Nasdaq: SGXP ) today announced that ... leading proxy advisory firms, have,recommended that SGX stockholders vote ... LLY ) at the SGX Special Stockholders Meeting,scheduled ... The Board of Directors of SGX unanimously recommends ...
Cached Biology Technology:Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results 2Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results 3Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results 4Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results 5Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results 6DOE JGI Director Eddy Rubin highlights the genomics of plant-based biofuels in the journal Nature 2DOE JGI Director Eddy Rubin highlights the genomics of plant-based biofuels in the journal Nature 3DOE JGI Director Eddy Rubin highlights the genomics of plant-based biofuels in the journal Nature 4SGX - Lilly Merger Offer Receives Positive Opinions From Proxy Advisory Firms 2SGX - Lilly Merger Offer Receives Positive Opinions From Proxy Advisory Firms 3SGX - Lilly Merger Offer Receives Positive Opinions From Proxy Advisory Firms 4
(Date:7/24/2014)... Scientists at The New York Stem Cell Foundation ... creating a viable cell replacement therapy for multiple ... For the first time, NYSCF scientists generated induced ... of patients with primary progressive multiple sclerosis and ... these stem cells into becoming oligodendrocytes, the myelin-forming ...
(Date:7/24/2014)... Citing many sobering examples of how wildlife loss leads ... article co-authored by Wildlife Conservation Society (WCS) Health ... Christopher Golden, calls for an interdisciplinary approach to tackle ... directly supports about 15% of the world,s people and ... world,s poor. It should come as no surprise that ...
(Date:7/24/2014)... New York, NY - July 24, 2014 -- Keryx ... results from the long-term, randomized, active control Phase 3 ... ferric iron-based phosphate binder, for the treatment of hyperphosphatemia ... The PERFECTED study (PhosphatE binding and iRon delivery with ... the Journal of the American Society of Nephrology ...
Breaking Biology News(10 mins):NYSCF scientists one step closer to cell therapy for multiple sclerosis patients 2New study draws links between wildlife loss and social conflicts 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4
... influenza caused widespread death and illness in 1918, 1957, 1968 ... time of these pandemics finds that each of them was ... study,s authors--Jeffrey Shaman of Columbia University,s Mailman School of Public ... Healthnote that the La Nia pattern is known to alter ...
... new varieties of corn with a higher yield faster than ... Germany, and other institutions are relying on a trick: early ... chemical and genetic makeup, as well as on new statistical ... authoritative journal Nature Genetics on Sunday evening, Jan. ...
... proteins have characteristic ways of "walking," which (also like human ... have discovered the unique "drunken sailor" gait of dynein, a ... in the body and whose malfunction has been associated with ... The research, which was led by Samara Reck-Peterson ...
Cached Biology News:Does the La Niña weather pattern lead to flu pandemics? 2Good parents are predictable -- at least when it comes to corn 2Good parents are predictable -- at least when it comes to corn 3Good parents are predictable -- at least when it comes to corn 4Walk this way: Scientists and MBL physiology students describe how a motor protein 'steps out' 2
... the principal excitatory neurotransmitter receptors ... glutamate receptors exist: Ionotropic receptors, ... receptors are oligomeric complexes of ... which comprise ligand-gated calcium channels. ...
Recommended fro Western blotting application...
... KLF15 is a Cys2-His2 zinc finger gene. ... liver, kidneys, heart, and skeletal muscle. ... produced in rabbits immunized with a synthetic ... KLF15 with an internal ID of P03590 ...
... Sac-Cel (Second Antibody Coated CELlulose) was developed ... of Dartford, Kent, one of the earliest ... IDS acquired the product range in 1987. ... clinical biochemists developing their own "in house" ...
Biology Products: